Does cartilage thickness change differ between ACL deficient knees with and without reconstruction surgery  by Wirth, W. et al.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62 S33Purpose: There is a high unmet medical need for disease modifying
drugs in OA that have an effect on joint structure. Fibroblast growth
factor 18 (FGF18) promotes chondrocyte proliferation and stabilizes an
anabolic chondrocyte phenotype. Data from a proof-of-concept trial in
knee OA demonstrated that sprifermin (rhFGF18) increased total
cartilage volume and thickness. This effect seemed to be more
pronounced in the lateral compartment, raising the question of the
distribution of the effect on cartilage change on different knee subre-
gions. Here we use a location-independent analysis method, to identify
whether sprifermin modiﬁes the magnitude of (subregional) cartilage
loss compared with placebo, independent of the location where it
occurs in individual joints.
Methods: Study participants (n¼168; 40-year-old; 69% female) had
symptomatic and radiographic femorotibial OA (KLG2 or 3), and were
not conﬁned to medial disease. Sprifermin (10, 30, or 100mg) or placebo
were injected once weekly for 3 weeks after randomization, and at 13
weeks. 1.5mm coronal SPGR MRIs were acquired at baseline and 13, 26
and 52 weeks. Medial (MFTC) and lateral femorotibial cartilage (LFTC)
was segmented by 7 readers, with blinding to acquisition order and
treatment (Chondrometrics GmbH). Cartilage thickness (changes) were
computed in each of 16 femorotibial subregions (5 medial and 5 lateral
tibial, 3 medial and 3 lateral femoral).The location-independent
magnitude of subregional thickness changes (in mm) was calculated
using ordered values (OV), individually assigning the magnitude of
cartilage loss in the subregion with the greatest loss to OV1, the one
with the second greatest loss to OV2, and so forth, and the one with the
smallest loss/greatest increase to OV16). In the current analysis, results
of the 100mg cohort (n¼63) vs. matching placebo (n¼21) were
compared using t-tests.
Results: Total femorotibial cartilage thickness loss at 52 weeks was less
in sprifermin treated than in placebo treated knees, with effects being
signiﬁcant in LFTC (p¼0.03) but not MFTC (p¼0.16) (Table 1). Signiﬁcant
treatment effects (p<0.05) were detected in 2/16 subregions (minimal
p-value ¼0.006 in the external lateral femur), and in 10/16 OVs
(minimal p¼0.004 in OV12). The 10 OVs included some in which
cartilage loss was observed (OV4-8) and some in which cartilage
thickening was observed in the placebo group (OV11-15).
Conclusions: This location-independent analysis shows that sprifermin
can modify the magnitude of cartilage loss in subregions with low OVs,
where (individual) mechanical challenges may be greater and drug
effects may be more important clinically. The OV approach also has the
advantage that no single region must be deﬁned a priori as structural
endpoint, which is challenging given spatial inter-subject heterogeneity
of (subregional) cartilage loss in OA, particularly in cohorts without
predeﬁned (medial or lateral) involvement. The results further show
that OVs are more effective and informative in revealing structural
treatment effects than region-based analysis, and that sprifermin not
only increases cartilage thickness (in regions where no loss is observed),
but actually reduces cartilage loss (in regions where cartilage loss is
observed with placebo).Table 1
Cartilage thickness change (mm) in sprifermin treated vs. placebo knees
Placebo
Mean  SD change
100mg dose




MFTC -0.07  0.18 0.00  0.16 0.43 0.1603
LFTC -0.04  0.19 0.04  0.12 0.58 0.0323
SRmax -0.03  0.11 0.04  0.09 0.78 0.0055
OV1 -0.22  0.16 -0.18  0.15 0.25 0.3529
OV2 -0.15  0.12 -0.12  0.12 0.25 0.3500
OV3 -0.12  0.09 -0.09  0.09 0.39 0.1571
OV4 -0.10  0.08 -0.05  0.07 0.64 0.0198
OV5 -0.08  0.07 -0.04  0.06 0.73 0.0094
OV6 -0.07  0.06 -0.02  0.06 0.79 0.0057
OV7 -0.05  0.06 -0.01  0.06 0.69 0.0132
OV8 -0.03  0.06 0.01  0.05 0.62 0.0244
OV9 -0.01  0.06 0.02  0.05 0.50 0.0708
OV10 0.01  0.06 0.03  0.05 0.49 0.0739
OV11 0.02  0.06 0.05  0.05 0.64 0.0210
OV12 0.03  0.07 0.06  0.04 0.80 0.0044
OV13 0.04  0.06 0.08  0.05 0.78 0.0065
OV14 0.07  0.07 0.10  0.05 0.64 0.0232
OV15 0.09  0.07 0.13  0.06 0.60 0.0305
OV16 0.15  0.10 0.18  0.07 0.35 0.212450
MALALIGNMENT; A POSSIBLE TARGET FOR PREVENTION OF
INCIDENT KNEE OA IN MIDDLE-AGED OVERWEIGHT AND OBESE
WOMEN
J. Runhaar y, M. van Middelkoop y, M. Reijman y, D. Vroegindeweij z, E.H.
Oei y, S.M. Bierma-Zeinstra y. y Erasmus MC, Rotterdam, Netherlands;
zMaasstad Hosp., Rotterdam, Netherlands
Purpose: The present study evaluates the effects of malalignment and
its interaction with BMI on the onset of clinical and radiographic knee
osteoarthritis (OA) over a 2.5 year follow-up period in a high risk group
of middle-aged overweight and obese women.
Methods: Data of the PROOF study (ISRCTN 42823086) were used. In
total, 407 women between 50 and 60 years, with a BMI 27 kg/m2, and
without clinical and radiological knee OA at baseline were included in
this study. Both knees of all 351 women (86%) with baseline knee
alignment data and the primary outcome available were selected. At
baseline, body weight and height were measured and standardized
semi-ﬂexed PA radiographs of both knees were taken according to the
MTP protocol. All subjects ﬁlled in a questionnaire with questions on
knee complaints and number of days with knee pain. All measurements
were repeated after 2.5 years of follow-up. Minimal joint space width
(medial and lateral), K&L grade and anatomical knee alignment angle
were digitally assessed on all radiographs. Varus alignment was deﬁned
as an anatomical angle 184. The predeﬁned primary outcome measure
was the incidence of knee OA, deﬁned as onset of K&L 2 or the onset of
clinical knee OA (according to the ACR criteria), or joint space narrowing
(JSN) 1.0 mm in themedial or lateral compartment. Using Generalized
Estimated Equations, which takes into account the correlation between
knees within subjects, effects of varus and valgus alignment on the
primary outcome and on the items separately were evaluated, with
neutrally aligned knees serving as reference. The interaction between
malalignment and baseline BMI was also studied, by adding BMI and
the interaction term with malalignment to the analysis. If a signiﬁcant
interactionwas found, overweight (BMI< 30 kg/m2) and obese subjects
(BMI  30 kg/m2) were analysed separately. All analyses were adjusted
for K&L grade at baseline and the randomized groups of the interven-
tions of the PROOF study.
Results: Varus alignment was found in 40% and valgus alignment in 13%
of all knees. Baseline characteristics are presented in Table 1. Overall,
only varus alignment had a signiﬁcant effect on the incidence of K&L 2
(9% vs. 3% in neutral knees. OR 2.8, 95% CI 1.3 - 5.9). For the primary
outcome and for medial JSN a signiﬁcant interaction between mala-
lignment and baseline BMI was found (p < 0.01). In obese subjects,
varus alignment had a signiﬁcant effect on the primary outcome (22%
vs. 13% in neutral knees. OR 1.8, 95% CI 1.1 - 3.1) and on medial JSN (9%
vs. 4% in neutral knees. OR 2.6, 95% CI 1.1 - 6.3). These associations were
not found in non-obese subjects.
Conclusions: In women at high risk for developing knee OA, varus
aligned knees had a signiﬁcant increased risk for the development of
radiographickneeOA.Withinobesewomen, varus alignedknees alsohad
a signiﬁcantly increased risk for incidence of knee OA according to the
primary outcome and for joint space narrowing in the medial compart-
ment. Since varus alignment is a potentially modiﬁable factor, results
from the present study suggest that varus alignmentmight be a target for
the prevention of knee OA inmiddle-aged overweight and obesewomen.51
DOES CARTILAGE THICKNESS CHANGE DIFFER BETWEEN ACL
DEFICIENT KNEES WITH ANDWITHOUT RECONSTRUCTION SURGERY
W. Wirth y, F. Eckstein y, M. Hudelmaier y, S. Lohmander z, R.
Frobell z. y Paracelsus Med. Univ., Salzburg, Austria; zOrthopedics,
Clinical Sci. Lund, Lund Univ., Lund, Sweden
Purpose: An ACL tear is a common knee injury, involving a serious
trauma and a subsequent period of chronic alterations in joint biome-
chanics. The risk of developing incident knee OA after an ACL tear is
known to be highly elevated although the driving mechanisms are not
known. In this study, we tested the hypothesis that treatment of the
initial injury inﬂuenced change in femorotibial cartilage thickness over
the ﬁrst ﬁve years after injury. We thus explored femorotibial cartilage
thickness changes during the ﬁrst 2 years (BL/Y2) and during
a subsequent three-year period (Y2/Y5) after an acute ACL tear.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62S34Methods: 121 young (32 women, mean age 26.1 years) active adults
with an acute ACL tear in a previously un-injured knee were included in
a treatment RCT (the KANON-trial). Patients were randomized to either
rehabilitation plus early ACL reconstruction (ACLR, n¼62) or rehabili-
tation plus the option of having a delayed ACLR if needed (n¼59).
During the 5 year follow up period, 30 (51%) of those randomized to the
latter group had a delayed ACLR. A complete set of sagittal MR images
for baseline, 2, and 5 year follow-up was available for 106 participants.
Cartilage thickness (ThC) was assessed by manual segmentation of the
femorotibial cartilages with blinding to time point and treatment group.
Mean change in ThC in the medial femorotibial compartment (MFTC)
was considered the primary and subregions with the largest decrease
(ordered value 1 ¼ OV1) or increase in ThC (OV16) were considered
secondary outcomes. ThC changes were analyzed according using an
‘as-treated’ approach (57 with early ACLR; 25 with delayed ACLR; 24
with rehabilitation alone) using the t-test (crude differences) and
analysis of covariance (differences with adjustment for age, sex & BMI).
Results: The mean increase of ThC in MFTC between BL/Y2 of knees
treated with rehab alone tended to be smaller than in knees treated
with early ACLR, but the difference was not statistically signiﬁcant
(crude/adjusted p¼0.18 / p¼0.16, Table 1). In the same period, the ThC
increase in MFTC of knees with delayed ACLR did not differ signiﬁcantly
from increase in knees with early ACLR (crude/adjusted p¼0.45 /
p¼0.31) or knees without ACLR (p¼0.68 / p¼0.75 for crude/adjusted
differences). In the subsequent observation period between Y2/Y5, no
signiﬁcant differences were observed between the three groups (crude/
adjusted p>¼0.42/0.55).
In the period from BL/Y2, OV 1was signiﬁcantlymore negative (crude/
adjusted p¼ 0.02/0.02) and OV 16 was signiﬁcantly more positive
(crude/adjusted p¼ 0.04/0.03) for knees with early ACLR than for knees
treated with rehab alone but differences were not signiﬁcant in the
subsequent period from Y2/Y5 (crude/adjusted p>¼0.09/0.14,
Table 1). In knees with delayed ACLR both OV 1 and OV 16 tended to
have a higher magnitude of change than in knees treated with rehab
alone (BL/>Y2: p>¼0.08/0.09 and Y2/Y5: p>¼ 0.07/0.04 for crude/
adjusted differences). No signiﬁcant differences were observed for OV1
and OV 16 between knees with delayed and early ACLR (crude/adjusted
p>¼ 0.18/0.23).
Conclusions: MFTC cartilage thickness increased after acute ACL tear
but this increase did not differ signiﬁcantly between knees treated with
(early or delayed) ACLR or knees treated with rehab alone. Our results
suggest that an ACLR, performed early or at a later stage, may induce
elevated magnitudes of subregional cartilage thickness change. This
effect appears to occur during the period immediately after trauma/
surgery but not in later periods.Mean change (MC) and 95% CI (um) in the medial compartment (MFTC),
ordered value (OV) 1, and OV 16.
Baseline/Year 2 Year 2/Year 5
MC 95% CI MC 95% CI
Early ACLR MFTC 63 [21, 105] 59 [24, 94]
(n¼57) OV 1 -261 [-307, -215] -167 [-196, -138]
OV 16 246 [212, 280] 204 [179, 230]
Delayed ACLR MFTC 32 [-45, 110] 85 [30, 140]
(n¼25) OV 1 -239 [-301, -177] -191 [-253, -129]
OV 16 230 [174, 285] 235 [198, 272]
No ACLR MFTC 13 [-45, 70] 82 [28, 135]
(n¼24) OV 1 -174 [-214, -134] -122 [-167, -78]
OV 16 183 [138, 229] 186 [147, 225]52
EXCLUSION OF PATIENTS WITH SEQUENTIAL PRIMARY HIP OR KNEE
REPLACEMENTS OVERESTIMATES THE RATES OF COMPLICATIONS
FOLLOWING JOINT REPLACEMENT
B. Ravi y, R. Croxford z, G.A. Hawker y. yUniv. of Toronto, Toronto, ON,
Canada; z Inst. of Clinical Evaluative Sci. (ICES), Toronto, ON, Canada
Purpose: Total joint arthroplasty (TJA) outcome studies have largely
focused on recipients of a single primary TJA, excluding those with
sequential TJAs during follow-up. The objectives of our study were to
determine the proportion of ﬁrst-time TJA recipients who go on toreceive a subsequent TJAwithin two years of their index procedure, and
to compare the demographic characteristics and rates of complications
following the index arthroplasty for TJA recipients who did versus did
not receive a subsequent elective primary TJA within two years.
Methods:Wedeﬁned a cohortof patientswhoreceived theirﬁrst primary
elective TJA of the hip or knee for osteoarthritis (OA) between 2002-2009
utilizing health administrative data from Ontario, Canada. We excluded
those who had received a primary or revision TJA prior to April 1, 2002,
whose ﬁrst procedure was non-elective (e.g. for cancer, fracture, or
external cause of injury), and with a diagnosis of inﬂammatory arthritis.
We compared baseline characteristics and rates of complications
following the index arthroplasty for thosewho received a subsequent TJA
within 2y versus (‘multiple’ group) and thosewho did not (‘single’ group).
Logistic regressionwasused to determine the relationshipbetween group
(single versus multiple) and the occurrence of one ormore complications
associated with the index TJA, after controlling for covariates.
Results: Between April 1, 2002 and March 31, 2009, there were 97,374
patients who received their ﬁrst primary elective TJA (37,670 index
THAs and 59,704 index TKAs). Over the two-year follow-up from the
index TJA, 24.5% of TKA recipients and 16.7% of THA recipients received
a second TJA procedure. For the majority (w95%) of these individuals,
the second procedure was a primary elective TJA of another hip or knee
(20.4% of the entire cohort).
Compared with recipients of a single primary, elective TJA, recipients of
multiple primary, elective TJAs were more likely to be female (60.5%
versus 57.2%, p<0.0001), were younger (mean age 66.6y versus 67.1y,
p<0.0001), had less comorbidity (Charlson score of 2+: 3.7% versus 4.3%,
p<0.0001), were more likely to have received an index knee versus hip
TJA (70% versus 59%, p<0.0001), had a shorter length of stay (4.7d versus
4.9d, p¼0.0011), and were less likely to receive their index TJA at
a teaching hospital (28.6% versus 30.6%, p<0.0001). Patients in the
multiple group also had lower rates of complications following the index
arthroplasty, including early revision (0.6% versus 1.3%, p<0.0001), and
the occurrence of any complication (including DVT, PE, AMI, infection,
and revision) (2.4% versus 3.8%, p<0.0001). Controlling for other factors,
a subsequent primary TJA was associated with fewer complications
following the index arthroplasty (adjusted OR 0.65, 95%CI 0.59-0.72).
Conclusions: In a population inception cohort undergoing their ﬁrst
primary elective hip or knee TJA, one in ﬁve patients went on to receive
a secondprimaryelective TJAwithin2years of the indexprocedure. These
individuals were systematically different from patients who did not have
a subsequent primary TJA. Patientswith sequential TJAswere, onaverage,
healthier than those who did not, and were also less likely to have
experienced a serious surgical complication related to the index proce-
dure. Collectively, these results suggest that the routine exclusion of this
substantial subgroup of patients from TJA outcomes studies results in
systematic overestimation of the overall rates of surgical complications,
and thus potentially underestimates patient-reported beneﬁts.53
POSTOPERATIVE EFFECTS OF NEUROMUSCULAR EXERCISE PRIOR TO
HIP OR KNEE ARTHROPLASTY - A RANDOMISED CONTROLLED TRIAL
A. Villadsen y, S. Overgaard z, A. Holsgaard-Larsen z, R. Christensen y,x, E.
Roos y. yRes. unit for musculoskeletal function and physiotherapy, Inst. of
Sport Sci. & Clinical Biomechanics, Univ. of Southern Denmark, Odense,
Denmark; zOrthopaedic Res. Unit, Odense Univ. Hosp., Inst. of Clinical
Res., Univ. of Southern Denmark, Odense, Denmark; xMusculoskeletal
Statistics Unit, The Parker Inst., Copenhagen Univ. Hosp. at
Frederiksberg, Copenhagen, Denmark
Purpose: To investigate the postoperative efﬁcacy of a supervised
programme of neuromuscular exercise (NEMEX-TJR) prior to hip or
knee arthroplasty.
Methods:
Design: Randomised, assessor-blinded, controlled trial.
Setting OUH Svendborg Hospital (regional), Odense University Hospital,
Region of Southern Denmark.
Participants: 165 patients scheduled for hip or knee arthroplasty due to
severe osteoarthritis
Interventions: An 8-week preoperative neuromuscular supervised
exercise programme was delivered twice a week for one hour as an
adjunct treatment to the standard arthroplasty procedure and
compared with the standard arthroplasty procedure alone.
